secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-002848
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools reports preliminary FY2024 revenue ~$174M; Q4 ~$46.5M
-----------------------------------------------------------------------

- Preliminary Q4 2024 revenue approximately $46.5 million.
- Full year 2024 revenue approximately $174 million, at top end of revised guidance.
- CEO cites industry-wide headwinds and progress reducing operating expenses via SBS.
- Company to discuss 2025 outlook when reporting final Q4/FY results later in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000110465925002848/0001104659-25-002848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000110465925002848/tm252898d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer